Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
As the founder of BHMP Network, Abiola Mariah will explore how inclusive and adaptive leadership practices, informed by QA principles, can strengthen regulatory compliance, foster innovation, and drive equitable outcomes.
The agenda will cover the evolving landscape of life sciences, key leadership challenges, core and essential skills such as emotional intelligence, collaboration, continuous learning, and accountability, all supported by real-world case studies to provide practical strategies for leadership development.
Cost: £10
In this session, Arkivum team members Rob Buckton and Tom Lynam will explore everything you need to know about retaining essential GCP records and data. This includes:
- Why retention matters, expanding on key retention regulations (EU CTR, MHRA updates and more).
- What good looks like taking into account ICH E6(R3) and ALCOA+.
- How to move towards good and why digital safeguarding and preservation are both crucial.
- How to implement a risk based approach to retention.
- Why data sprawl is a challenge and how consolidation supports compliance.
This session is presented by Lauren MIlls and Joeeta Murphy from iP21 and will explore how IP can be strategically leveraged to drive innovation and commercial success in the Life Sciences sector. From patents protecting cutting-edge biotechnologies and pharmaceuticals to trade marks and design rights supporting brand identity and product differentiation, we’ll examine the key IP tools available to researchers, startups, and established companies. The talk will also cover common pitfalls, ownership issues, collaboration agreements, and the role of software and data in life sciences.
OXFORD, UK and PORTLAND, ME – 25 November 2025 – Ovation.io, a leading human omics and clinical data company, and PrecisionLife, a precision medicine company transforming how complex chronic diseases are understood and managed, today announced a collab
Who we are:
Life, Reimagined
Constructive Bio is a VC-backed biotechnology startup based in Whittlesford, Cambridge. Our unique technology turns living cells into biofactories, creating sustainable new materials and therapeutics. With full control of the genetic sequence and code, we are exploring chemical space previously unreached by natural biology.
24 November 2025, Paris, France / Biocair, an established global leader in life science logistics, today announced the relocation of its Paris facility to a new, substantially larger premises strategically positioned within the Paris-Charles de Gaulle airport cargo zone. This move strengthens Biocair’s presence in the geographical and logistical center of one of Europe’s major transport hubs.
Edinburgh and Cambridge, UK, 25 November 2025 - Macomics Ltd, a leader in macrophage drug discovery, announces that it has validated its ENIGMAC™ platform in macrophage mediated antifibrotic therapy.
Macomics’ ENIGMAC drug discovery platform is designed to discover therapeutic targets and unlock disease specific target biology. The platform enables identification and validation of novel targets and provides a translationally relevant path to the clinic through the development of more physiologically relevant human models combined with proprietary gene editing technology.
bit.bio is an award-winning spinout from the University of Cambridge. Our breakthrough technology combines synthetic and stem cell biology for the precise, efficient and consistent reprogramming of human cells used in research, drug discovery, and cell therapy. At bit.bio, we are passionate about engineering human cells that will enable the medicine of the future. To do this we need talented and curious people who want to make an impact on the future of science and therapeutics.
Creative Biolabs is rewriting the methods scientists use to develop binders and antibodies in the changing environment of therapeutic discovery. The company, which has a set of advanced platforms, is, therefore, a partner that many researchers can hardly do without as they go deeper into the most challenging molecular frontiers.